Compare WFF & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WFF | BOLT |
|---|---|---|
| Founded | 1984 | 2015 |
| Country | Malaysia | United States |
| Employees | 138 | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3M | 10.5M |
| IPO Year | N/A | 2021 |
| Metric | WFF | BOLT |
|---|---|---|
| Price | $0.44 | $4.09 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $34.00 |
| AVG Volume (30 Days) | ★ 514.7K | 24.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,690,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.34 | $0.26 |
| 52 Week High | $29.22 | $7.35 |
| Indicator | WFF | BOLT |
|---|---|---|
| Relative Strength Index (RSI) | 53.29 | 33.03 |
| Support Level | $0.38 | $0.28 |
| Resistance Level | $0.52 | $5.45 |
| Average True Range (ATR) | 0.06 | 0.41 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 38.71 | 10.85 |
WF Holding Ltd is a manufacturer of FRP products based in Malaysia. It has been providing high-quality and durable FRP products to various industries, including, among others, chemical processing, water and wastewater treatment, and power generation. Its products range from tanks, pipes, ducts, gratings and other custom-made FRP products. The company uses advanced production technology and equipment and has obtained various certifications. Its manufacturing capabilities allow the company to design and fabricate products that meet the specific needs of its clients, ensuring high-quality and reliable performance.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.